Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whether they were treated with sacituzumab govitecan-hziy (Trodelvy) or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback